X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-03-08 | DYN | High Susanna Gatti | COO | S - Sale | $26.59 | -29,491 | 156,800 | -16% | -$784,248 | |||||
| DM | 2024-03-08 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $26.11 | -109,601 | 139,408 | -44% | -$2,861,373 | |||||
| M | 2024-03-11 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.65 | -2,615 | 150,560 | -2% | -$67,082 | |||||
| DM | 2024-03-08 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $26.19 | -88,924 | 119,283 | -43% | -$2,329,007 | |||||
| DM | 2024-03-08 | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $25.89 | -429,730 | 537,998 | -44% | -$11,125,776 | |||||
2024-03-11 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $25.70 | -2,081 | 152,352 | -1% | -$53,482 | ||||||
2024-03-07 | DYN | Brumm Joshua T | CEO, Pres | S - Sale | $25.85 | -9,086 | 554,385 | -2% | -$234,873 | ||||||
2024-03-07 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $25.85 | -2,373 | 154,433 | -2% | -$61,342 | ||||||
2024-03-07 | DYN | High Susanna Gatti | COO | S - Sale | $25.85 | -1,591 | 186,291 | -1% | -$41,127 | ||||||
2024-03-07 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.86 | -9,921 | 153,175 | -6% | -$256,585 | ||||||
2024-03-07 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $25.85 | -2,434 | 141,184 | -2% | -$62,919 | ||||||
2024-03-07 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $25.85 | -2,273 | 121,955 | -2% | -$58,757 | ||||||
2024-03-01 | DYN | Rhodes Jason P | Dir | S - Sale | $30.05 | -46,534 | 6,545,479 | -1% | -$1,398,347 | ||||||
2024-03-01 | DYN | Atlas Venture Opportunity Fund I, L.P. | 10% | S - Sale | $30.05 | -46,534 | 2,306,079 | -2% | -$1,398,347 | ||||||
| DM | 2024-02-29 | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $28.96 | -100,000 | 563,471 | -15% | -$2,895,519 | |||||
| DM | 2024-02-29 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $28.46 | -28,528 | 143,618 | -17% | -$811,865 | |||||
| DM | 2024-02-29 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $28.05 | -12,740 | 124,228 | -9% | -$357,296 | |||||
| M | 2024-02-26 | DYN | Rhodes Jason P | Dir | S - Sale | $24.30 | -807,838 | 864,487 | -48% | -$19,626,903 | |||||
| M | 2024-02-26 | DYN | Atlas Venture Fund Xi, L.P. | 10% | S - Sale | $24.30 | -807,838 | 6,562,578 | -11% | -$19,626,903 | |||||
| M | 2024-02-21 | DYN | Rhodes Jason P | Dir | S - Sale | $22.64 | -500,789 | 920,843 | -35% | -$11,339,780 | |||||
| M | 2024-02-21 | DYN | Atlas Venture Fund Xi, L.P. | 10% | S - Sale | $22.64 | -500,789 | 7,273,405 | -6% | -$11,339,780 | |||||
| M | 2024-02-15 | DYN | Rhodes Jason P | Dir | S - Sale | $23.26 | -510,152 | 9,359,331 | -5% | -$11,867,292 | |||||
| M | 2024-02-15 | DYN | Atlas Venture Fund Xi, L.P. | 10% | S - Sale | $23.26 | -510,152 | 6,815,965 | -7% | -$11,867,292 | |||||
2024-02-12 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.07 | -5,493 | 163,503 | -3% | -$137,710 | ||||||
2024-01-26 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $25.00 | -100 | 168,996 | 0% | -$2,500 | ||||||
| D | 2024-01-26 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $24.53 | -20,000 | 143,618 | -12% | -$490,510 | |||||
| D | 2024-01-26 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $24.34 | -13,000 | 124,228 | -9% | -$316,420 | |||||
2024-01-09 | DYN | Kersten Dirk | Dir, 10% | P - Purchase | $17.50 | +1,714,285 | 1,428,571 | -600% | +$29,999,988 | ||||||
| DM | 2024-01-03 | DYN | Brumm Joshua T | CEO, Pres | S - Sale+OE | $18.66 | -269,719 | 584,971 | -32% | -$5,032,915 | |||||
| DM | 2024-01-03 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale+OE | $18.57 | -87,779 | 156,806 | -36% | -$1,629,985 | |||||
| DM | 2024-01-02 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale+OE | $16.59 | -31,900 | 143,618 | -18% | -$529,194 | |||||
| D | 2024-01-03 | DYN | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale+OE | $18.81 | -13,000 | 124,228 | -9% | -$244,530 | |||||
2023-12-14 | DYN | Scalzo Richard William | See Remarks | S - Sale | $12.02 | -2,376 | 124,228 | -2% | -$28,560 | ||||||
2023-12-11 | DYN | Scalzo Richard William | See Remarks | S - Sale | $10.72 | -1,380 | 126,604 | -1% | -$14,794 | ||||||
2023-12-11 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $10.72 | -1,245 | 155,518 | -1% | -$13,346 | ||||||
2023-12-11 | DYN | High Susanna Gatti | COO | S - Sale | $10.72 | -1,616 | 187,882 | -1% | -$17,324 | ||||||
| M | 2023-12-11 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $10.66 | -2,666 | 169,096 | -2% | -$28,413 | |||||
2023-12-11 | DYN | Brumm Joshua T | See Remarks | S - Sale | $10.72 | -7,585 | 584,971 | -1% | -$81,311 | ||||||
2023-12-11 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $10.72 | -1,467 | 176,585 | -1% | -$15,726 | ||||||
| M | 2023-12-04 | DYN | Scalzo Richard William | See Remarks | S - Sale | $12.01 | -2,553 | 127,984 | -2% | -$30,662 | |||||
2023-11-02 | DYN | High Susanna Gatti | COO | S - Sale | $7.40 | -9,939 | 94,605 | -10% | -$73,549 | ||||||
2023-09-18 | DYN | Scalzo Richard William | See Remarks | S - Sale | $9.41 | -1,290 | 40,795 | -3% | -$12,139 | ||||||
2023-09-18 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $9.41 | -1,261 | 60,605 | -2% | -$11,866 | ||||||
2023-09-18 | DYN | High Susanna Gatti | COO | S - Sale | $9.41 | -2,672 | 104,544 | -2% | -$25,144 | ||||||
2023-09-18 | DYN | Brumm Joshua T | See Remarks | S - Sale | $9.41 | -12,032 | 233,679 | -5% | -$113,221 | ||||||
2023-09-18 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $9.41 | -1,436 | 84,334 | -2% | -$13,513 | ||||||
2023-09-12 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $10.41 | -1,707 | 89,250 | -2% | -$17,770 | ||||||
2023-09-12 | DYN | Scalzo Richard William | See Remarks | S - Sale | $10.41 | -1,397 | 42,085 | -3% | -$14,543 | ||||||
2023-09-12 | DYN | McNeill Jonathan | Chief Business Officer | S - Sale | $10.41 | -1,266 | 61,866 | -2% | -$13,179 | ||||||
2023-09-12 | DYN | High Susanna Gatti | COO | S - Sale | $10.41 | -1,635 | 107,216 | -2% | -$17,020 | ||||||
2023-09-12 | DYN | Brumm Joshua T | See Remarks | S - Sale | $10.41 | -7,672 | 245,711 | -3% | -$79,866 | ||||||
2023-09-12 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $10.41 | -1,484 | 85,770 | -2% | -$15,448 | ||||||
| DM | 2023-06-13 | DYN | Scalzo Richard William | See Remarks | S - Sale+OE | $12.71 | -51,390 | 43,482 | -54% | -$653,178 | |||||
| M | 2023-06-12 | DYN | McNeill Jonathan | See Remarks | S - Sale | $12.68 | -2,259 | 63,132 | -3% | -$28,649 | |||||
2023-06-13 | DYN | High Susanna Gatti | COO | S - Sale | $12.43 | -1,625 | 108,851 | -1% | -$20,199 | ||||||
2023-06-13 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $12.43 | -1,698 | 90,957 | -2% | -$21,106 | ||||||
2023-06-13 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $12.43 | -1,475 | 87,254 | -2% | -$18,334 | ||||||
| DM | 2023-06-08 | DYN | Brumm Joshua T | See Remarks | S - Sale+OE | $12.90 | -325,330 | 253,383 | -56% | -$4,195,797 | |||||
2023-03-14 | DYN | Scalzo Richard William | See Remarks | S - Sale | $13.33 | -1,311 | 54,872 | -2% | -$17,476 | ||||||
| M | 2023-03-13 | DYN | McNeill Jonathan | See Remarks | S - Sale | $13.18 | -2,209 | 65,391 | -3% | -$29,116 | |||||
2023-03-14 | DYN | High Susanna Gatti | COO | S - Sale | $13.33 | -1,559 | 110,476 | -1% | -$20,781 | ||||||
2023-03-14 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale | $13.33 | -7,441 | 92,655 | -7% | -$99,189 | ||||||
2023-03-14 | DYN | Brumm Joshua T | See Remarks | S - Sale | $13.33 | -7,318 | 322,483 | -2% | -$97,549 | ||||||
2023-03-14 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $13.33 | -1,416 | 88,729 | -2% | -$18,875 | ||||||
| D | 2023-01-18 | DYN | McNeill Jonathan | See Remarks | S - Sale+OE | $14.03 | -10,000 | 67,600 | -13% | -$140,300 | |||||
2023-01-09 | DYN | McNeill Jonathan | See Remarks | S - Sale | $11.57 | -30,150 | 67,600 | -31% | -$348,836 | ||||||
2022-12-12 | DYN | Rhodes Jason P | Dir | P - Purchase | $10.70 | +934,581 | 9,869,483 | +10% | +$10,000,017 | ||||||
2022-12-12 | DYN | Atlas Venture Opportunity Fund Ii, L.P. | 10% | P - Purchase | $10.70 | +934,581 | 9,869,483 | +10% | +$10,000,017 | ||||||
| D | 2022-12-12 | DYN | Scalzo Richard William | See Remarks | S - Sale+OE | $10.87 | -312 | 56,183 | -1% | -$3,391 | |||||
| D | 2022-12-12 | DYN | McNeill Jonathan | See Remarks | S - Sale+OE | $10.87 | -472 | 97,750 | 0% | -$5,131 | |||||
| D | 2022-12-12 | DYN | High Susanna Gatti | COO | S - Sale+OE | $10.87 | -751 | 112,035 | -1% | -$8,163 | |||||
| D | 2022-12-12 | DYN | Farwell Wildon | Chief Medical Officer | S - Sale+OE | $10.87 | -628 | 100,096 | -1% | -$6,826 | |||||
| D | 2022-12-12 | DYN | Brumm Joshua T | See Remarks | S - Sale+OE | $10.87 | -3,322 | 329,801 | -1% | -$36,110 | |||||
| D | 2022-12-12 | DYN | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale+OE | $10.87 | -680 | 90,145 | -1% | -$7,392 | |||||
| DM | 2022-10-07 | DYN | Brumm Joshua T | See Remarks | S - Sale+OE | $12.52 | -210,000 | 189,123 | -53% | -$2,629,522 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |